3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Lung Diseases
2
Lung Non-Squamous Non-Small Cell Carcinoma
1
Lung Neoplasms
1
Carcinoma
1
Interventions
Carboplatin
7
Paclitaxel
4
Cisplatin
4
pembrolizumab
3
Pemetrexed
3
zipalertinib
2
selpercatinib
2
durvalumab
2
Nivolumab
2
Blood Specimen Collection
2
zimberelimab
1
taletrectinib
1
sotorasib
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
alectinib
1
Tomography, Emission-Computed, Single-Photon
1
Toll-Like Receptor 1
1
Telescopes
1
Surveys and Questionnaires
1
Radiosurgery
1
One-Lung Ventilation
1
Omacor
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Health Records, Personal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Diseases
×
zipalertinib
×
1 year
×
Clear all
NCT05967689
2026-05-28
REZILIENT2
Taiho Oncology, Inc.
Phase 2
Recruiting
220 enrolled
NCT05973773
2026-05-28
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled